Citadel Advisors
BTCY

Citadel Advisors’s Biotricity, Inc. Common Stock BTCY Stock Holding History

Citadel Advisors’s Portfolio BTCY Stock Details BTCY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-300
Closed -$354 – 15671
2023
Q4 		$354 Buy
+300
New +$400 ﹤0.01% 14052
2023
Q3 		– Sell
-9,900
Closed -$37.9K – 15358
2023
Q2 		$37.9K Buy
+9,900
New +$36.9K ﹤0.01% 12114
2022
Q2 		– Sell
-2,783
Closed -$38K – 14404
2022
Q1 		$38K Sell
2,783
-1,134
-29% -$19.7K ﹤0.01% 12974
2021
Q4 		$94K Buy
+3,917
New +$92.3K ﹤0.01% 12782

Other funds holding BTCY

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ARC
Advisor Resource Council Dallas, Texas $355M AUM 30.05% 1-Year Est. Return
SFCL
Strengthening Families & Communities LLC Boston, Massachusetts $401M AUM 33.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
TWC
TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return
CMA
Cedar Mountain Advisors Lake Oswego, Oregon $581M AUM 18.16% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return

Citadel Advisors's BTCY Position: Q1 2024 in Review

Citadel Advisors sold out of Biotricity, Inc. Common Stock (BTCY) in Q1 2024, closing a stake of 21,637 shares — an estimated $25.5K sold.

Citadel Advisors first reported a position in BTCY in Q3 2021 and held it in 6 quarters. The position peaked at $133K in Q1 2022. 18 funds tracked by Wall St. Rank hold BTCY as of Q1 2024.

  • Citadel Advisors reported no remaining Biotricity, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Citadel Advisors sold 21,637 Biotricity, Inc. Common Stock shares in Q1 2024, an estimated $25.5K.
  • Citadel Advisors first reported a position in Biotricity, Inc. Common Stock in Q3 2021 and held it in 6 quarters.
  • Citadel Advisors's Biotricity, Inc. Common Stock position peaked at $133K in Q1 2022.
  • 18 funds tracked by Wall St. Rank held Biotricity, Inc. Common Stock as of Q1 2024.

Based on Citadel Advisors's 13F filing for Q1 2024, filed 15 May 2024.